Essex Investment Management Co. LLC grew its position in shares of Neos Therapeutics, Inc. (NASDAQ:NEOS) by 24.2% in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 238,152 shares of the company’s stock after buying an additional 46,423 shares during the quarter. Essex Investment Management Co. LLC owned 0.85% of Neos Therapeutics worth $2,179,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently made changes to their positions in the business. Dynamic Technology Lab Private Ltd purchased a new position in Neos Therapeutics during the 2nd quarter worth $118,000. State Street Corp raised its position in Neos Therapeutics by 29.6% during the 2nd quarter. State Street Corp now owns 316,855 shares of the company’s stock worth $2,312,000 after buying an additional 72,395 shares during the last quarter. DAFNA Capital Management LLC raised its position in Neos Therapeutics by 120.3% during the 2nd quarter. DAFNA Capital Management LLC now owns 209,873 shares of the company’s stock worth $1,532,000 after buying an additional 114,600 shares during the last quarter. Tudor Investment Corp ET AL purchased a new position in Neos Therapeutics during the 2nd quarter worth $146,000. Finally, HighTower Advisors LLC purchased a new position in Neos Therapeutics during the 2nd quarter worth $204,000. Institutional investors own 44.32% of the company’s stock.

Neos Therapeutics (NASDAQ:NEOS) last issued its quarterly earnings data on Tuesday, August 8th. The company reported ($0.83) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.83). Neos Therapeutics had a negative net margin of 511.74% and a negative return on equity of 611.78%. The business had revenue of $4.91 million for the quarter.

A number of brokerages have commented on NEOS. Cantor Fitzgerald set a $20.00 price objective on shares of Neos Therapeutics and gave the stock a “buy” rating in a research report on Wednesday. Zacks Investment Research upgraded shares of Neos Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday. Cowen and Company restated a “buy” rating on shares of Neos Therapeutics in a research report on Thursday, October 26th. Wells Fargo & Company set a $14.00 price objective on shares of Neos Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, October 18th. Finally, ValuEngine upgraded shares of Neos Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 12th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $14.00.

TRADEMARK VIOLATION NOTICE: “Essex Investment Management Co. LLC Has $2.18 Million Holdings in Neos Therapeutics, Inc. (NEOS)” was reported by Daily Political and is the property of of Daily Political. If you are reading this report on another website, it was copied illegally and reposted in violation of US and international copyright legislation. The correct version of this report can be accessed at https://www.dailypolitical.com/2017/11/03/essex-investment-management-co-llc-has-2-18-million-holdings-in-neos-therapeutics-inc-neos.html.

Neos Therapeutics Profile

Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).

Want to see what other hedge funds are holding NEOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neos Therapeutics, Inc. (NASDAQ:NEOS).

Institutional Ownership by Quarter for Neos Therapeutics (NASDAQ:NEOS)

Receive News & Ratings for Neos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.